Provided by Tiger Trade Technology Pte. Ltd.

Bionomics Limited

0.2531
0.0000
Volume:- -
Turnover:2.68M
Market Cap:4.94M
PE:-0.28
High:0.2531
Open:0.2531
Low:0.2531
Close:0.2531
52wk High:1.60
52wk Low:0.1770
Shares:19.53M
Float Shares:16.73M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9166
EPS(LYR):-1.5513
ROE:-55.39%
ROA:-41.41%
PB:0.29
PE(LYR):-0.16

Loading ...

Company Profile

Company Name:
Bionomics Limited
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.